Open AccessCardiovascular Disease in Patients With Type 2 Diabetes
Author(s) -
Elizabeth L. Ciemins,
Monette McKin,
Carol Hamersky,
N.C. Iyer,
Jill Powelson
Publication year - 2021
Publication title -
the journal of ambulatory care management/journal of ambulatory care management
Language(s) - English
Resource type - Journals
eISSN - 1550-3267
pISSN - 0148-9917
DOI - 10.1097/jac.0000000000000379
Subject(s) - medicine , guideline , disease , type 2 diabetes , type 2 diabetes mellitus , diabetes mellitus , intensive care medicine , disease management , medline , family medicine , health care , endocrinology , pathology , economic growth , parkinson's disease , political science , law , economics
Guidelines for the management of patients with type 2 diabetes mellitus (T2DM) recommend SGLT-2 (sodium-glucose cotransporter 2) inhibitors and GLP-1 RAs (glucagon-like peptide 1 receptor agonists) as second-line agents for patients with, or at risk for, cardiovascular disease. A better understanding of guideline implementation will further the provision of evidence-based health care to patients. Interviews and surveys of clinicians were conducted to understand providers' knowledge, attitudes, and beliefs related to the 2019 American Diabetes Association Standards of Care for T2DM. There was a lack of widespread knowledge of the guidelines and comfort with their use. Clinicians require additional training and education on the efficacy of the new medications and accompanying clinical guidelines.